Journal of Pharmacy Technology最新文献_第5页

Restriction Evaluation of Appropriate Carbapenem Therapy (REACT): A Multisite Observational Study. 适当碳青霉烯治疗的限制性评价（REACT）：一项多地点观察研究。

IF 1.3

Journal of Pharmacy Technology Pub Date : 2026-02-23 DOI: 10.1177/87551225261422672

Drew A Wells, Madison McKnight, Jessica Jaggar, Kerry O Cleveland, Alaina DeKerlegand

{"title":"Restriction Evaluation of Appropriate Carbapenem Therapy (REACT): A Multisite Observational Study.","authors":"Drew A Wells, Madison McKnight, Jessica Jaggar, Kerry O Cleveland, Alaina DeKerlegand","doi":"10.1177/87551225261422672","DOIUrl":"10.1177/87551225261422672","url":null,"abstract":"Introduction: Overuse of carbapenem antibiotics can lead to patient harm through adverse effects and further development of bacterial resistance. The purpose of this study was to investigate the sustained impact of meropenem restriction criteria on utilization volume and appropriateness. Methods: A retrospective observational study was conducted to evaluate meropenem restriction criteria among 5 adult hospitals (1 academic hospital and 4 community hospitals) in a single health system. Total meropenem days of therapy/1000 patient days (DOT/1000 PDs) and drug spending was compared before (January 2022) and after implementation (July 2023) were reviewed to investigate total impact of restriction criteria in the first year after implementation. Statistical comparisons used t tests or Mann-Whitney U tests for continuous data and chi square or Fisher's exact tests for categorical data; significance was defined as P < 0.05. Results: A total of 161 meropenem orders were included in this study, with 61 (39%) found to be inappropriate based on approved restriction criteria. The top 3 reasons for inappropriate meropenem use were undocumented or non-anaphylactic penicillin allergies (31%), lack of qualifying resistant organism within 3 months (26%), and starting meropenem prior to completing 48 hours of empiric therapy with cefepime or piperacillin/tazobactam (23%). The median meropenem DOT/1000 PD decreased from 40.5 to 20 (P < 0.001). Median monthly drug spend on meropenem across the hospital system decreased by 42% during the study period (P = 0.001). Conclusions: Meropenem restriction criteria across a multi-site health system can sustainably reduce carbapenem use and associated costs, supporting their continued adoption in antimicrobial stewardship policy.","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":" ","pages":"87551225261422672"},"PeriodicalIF":1.3,"publicationDate":"2026-02-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12929075/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147307094","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Stevens-Johnson Syndrome And Toxic Epidermal Necrolysis Possibly Related to Daptomycin And Ceftaroline in a Patient With Persistent Methicillin-Resistant Staphylococcus aureus Bacteremia: A Case Report and Brief Review. 持续性耐甲氧西林金黄色葡萄球菌菌血症患者的Stevens-Johnson综合征和中毒性表皮坏死松解可能与达托霉素和头孢他林有关：1例报告和简要回顾

IF 1.3

Journal of Pharmacy Technology Pub Date : 2026-02-23 DOI: 10.1177/87551225261422617

Nardine Karam Salgado, Jaina Patel, Stanley Moy

{"title":"Stevens-Johnson Syndrome And Toxic Epidermal Necrolysis Possibly Related to Daptomycin And Ceftaroline in a Patient With Persistent Methicillin-Resistant Staphylococcus aureus Bacteremia: A Case Report and Brief Review.","authors":"Nardine Karam Salgado, Jaina Patel, Stanley Moy","doi":"10.1177/87551225261422617","DOIUrl":"10.1177/87551225261422617","url":null,"abstract":"Objective: We report a unique case of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) possibly related to administering daptomycin and ceftaroline for persistent methicillin-resistant Staphylococcus aureus (MRSA) bacteremia. We describe treatment strategies and challenges of determining drug causality when multiple antimicrobials are administered. Case: A 78-year-old male developed SJS/TEN during week 6 of daptomycin and ceftaroline therapy. Other antimicrobials administered within the previous 8 weeks included vancomycin, meropenem, piperacillin/tazobactam, levofloxacin, and fluconazole. Causality was assessed using the Algorithm of Drug Causality for Epidermal Necrolysis, which indicated probable association with ceftaroline and possible association with daptomycin. Management included discontinuing both agents, transferring to a burn intensive care unit, wound care, and treatment with intravenous immunoglobulin. Discussion/Conclusion: Stevens-Johnson syndrome and toxic epidermal necrolysis associated with the use of daptomycin and ceftaroline is rare. Appropriate and timely diagnosis and management by a multidisciplinary team led to favorable clinical outcomes.","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":" ","pages":"87551225261422617"},"PeriodicalIF":1.3,"publicationDate":"2026-02-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12929076/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147307097","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Overview of Diabetes Medications: Traditional and New-Generation Agents and Their Off-Label Use for Weight Loss. 糖尿病药物综述：传统和新一代药物及其超说明书减肥应用

IF 1.3

Journal of Pharmacy Technology Pub Date : 2026-02-23 DOI: 10.1177/87551225261422610

Eleonora Castellana, Patricia Madalina Budau, Maria Rachele Chiappetta

{"title":"Overview of Diabetes Medications: Traditional and New-Generation Agents and Their Off-Label Use for Weight Loss.","authors":"Eleonora Castellana, Patricia Madalina Budau, Maria Rachele Chiappetta","doi":"10.1177/87551225261422610","DOIUrl":"10.1177/87551225261422610","url":null,"abstract":"Objective: Diabetes mellitus encompasses chronic metabolic disorders marked by impaired insulin secretion, action, or both, with type 1 and type 2 diabetes presenting distinct mechanisms and therapeutic needs. Achieving durable glycemic control remains essential to preventing microvascular and macrovascular complications. Data Sources: The growing prevalence of obesity among people with diabetes-driven by insulin resistance, lifestyle factors, and, in type 1 diabetes, insulin-associated weight gain-has increased the demand for therapies targeting both glycemia and body weight. Study Selection and Data Extraction: Traditional agents such as insulin, metformin, sulfonylureas, and thiazolidinediones have long served as treatment foundations but are limited by risks like hypoglycemia and weight gain. Incretin-based therapies, particularly glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose cotransporter 2 (SGLT-2) inhibitors, have reshaped diabetes care by improving glycemic control, promoting weight loss, and offering cardiovascular and renal protection. Data Synthesis: Newer dual and multiagonists, including tirzepatide and emerging triple agonists, show unprecedented reductions in HbA1c and body weight, approaching outcomes seen with bariatric surgery. However, rising off-label use of antidiabetic drugs for weight loss raises safety concerns, including gastrointestinal effects and rare motility disorders, underscoring the need for careful patient selection and pharmacovigilance. Conclusion: Ongoing challenges include high costs, inequities in access, medication shortages, and the need for sustained pharmacovigilance. Future directions involve oral non-peptide incretin mimetics, broader indications for multiagonists, and deeper understanding of long-term safety, particularly in off-label contexts.","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":" ","pages":"87551225261422610"},"PeriodicalIF":1.3,"publicationDate":"2026-02-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12929087/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147307168","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prevalence of Beta Blocker Prescribing for Hypertension. -受体阻滞剂处方高血压的患病率。

IF 1.5

Journal of Pharmacy Technology Pub Date : 2026-02-10 DOI: 10.1177/87551225261417534

Brandon J Skory, John Arko, Laila Terkawi, Emily Slusarz, Olivia King, Cynthia Deokarran, Kerstan Glista, Melanie Will, Hana Etemadi, Elisabeth Brosch, Erik Wasowski, Mate Michael Soric

{"title":"Prevalence of Beta Blocker Prescribing for Hypertension.","authors":"Brandon J Skory, John Arko, Laila Terkawi, Emily Slusarz, Olivia King, Cynthia Deokarran, Kerstan Glista, Melanie Will, Hana Etemadi, Elisabeth Brosch, Erik Wasowski, Mate Michael Soric","doi":"10.1177/87551225261417534","DOIUrl":"10.1177/87551225261417534","url":null,"abstract":"Background: Beta blockers are no longer recommended as first-line agents for hypertension (HTN) without compelling indications; however, evidence suggests that there is still frequent inappropriate prescribing of beta blockers to many US adults with HTN. Objective: To determine rate of prescribing of beta blockers for HTN without concurrent use of other first line antihypertensive agents. Methods: To analyze the validity of these claims, we utilized National Ambulatory Medical Care Survey data from 2013 to 2018 (excluding 2017). This data represented office visits related to adults receiving treatment for HTN. The data in the study encompasses 5191 unweighted visits representing 247 million visits nationally. Results: The data from these visits showed the prevalence of beta blocker prescribing to be 21.8% with 93.6% of beta blocker prescriptions considered inappropriate based on current guideline recommendations. This determination was made based on whether the patient had all first-line HTN treatment options prescribed prior to receiving beta blockade. Factors such as older age (≥65 years; odds ratio [OR] = 1.48, 95% CI = 1.11-1.97) and elevated blood pressure at the visit (OR = 1.43, 95% CI = 1.06-1.92) were associated with an increased likelihood of beta blocker prescribing, while depression (OR = 0.42, 95% CI = 0.24-0.73) and diabetes (OR = 0.70, 95% CI = 0.55-0.90) were associated with decreased likelihood. Conclusion: Inappropriate beta blocker prescribing for HTN without compelling indications remains highly prevalent in US outpatient practice. Older adults and patients with elevated blood pressure are particularly at risk. Targeted provider education and clinical decision support interventions are warranted to improve hypertension management.","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":" ","pages":"87551225261417534"},"PeriodicalIF":1.5,"publicationDate":"2026-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12890593/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146180459","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Maintaining Growth Hormone Therapy Adherence During Shortages: The Role of Specialty Pharmacy. 在短缺期间维持生长激素治疗依从性：专业药房的作用。

IF 1.5

Journal of Pharmacy Technology Pub Date : 2026-01-31 DOI: 10.1177/87551225261417940

Julie MacDougall, Heather Cournoyer

引用次数: 0

Short-Course Therapy for Uncomplicated VRE Bacteremia: This is Us Trying (to Shorten Therapy). 无并发症VRE菌血症的短期治疗：这是我们在尝试（缩短治疗）。

IF 1.5

Journal of Pharmacy Technology Pub Date : 2025-12-18 DOI: 10.1177/87551225251396748

Eleazar Torres, Nicole L Hlavacek, M Gabriela Cabanilla

{"title":"Short-Course Therapy for Uncomplicated VRE Bacteremia: This is Us Trying (to Shorten Therapy).","authors":"Eleazar Torres, Nicole L Hlavacek, M Gabriela Cabanilla","doi":"10.1177/87551225251396748","DOIUrl":"10.1177/87551225251396748","url":null,"abstract":"Background: The optimal treatment duration for uncomplicated vancomycin-resistant Enterococcus (VRE) bacteremia is unclear. Shorter courses may reduce adverse events (AEs) and hospital length of stay (LOS) without compromising clinical outcomes. Objective: To evaluate clinical outcomes associated with short-course (≤6 days) vs long-course (>6 days) therapy in hospitalized adults with uncomplicated VRE bacteremia. Methods: We conducted a single-center, retrospective study of adults with uncomplicated VRE bacteremia between 2014 and 2024. Patients who received ≤6 days of definitive antibiotic therapy were compared with those who received >6 days. The primary outcome was 30-day bacteremia recurrence. Secondary outcomes included infection-related readmission, 30- and 90-day all-cause mortality, post-bacteremia hospital LOS, and antibiotic-related AEs. Descriptive statistics, chi-square, and Fisher's exact tests were used. Results: Of the 48 patients included, 10 received short-course therapy and 38 received long-course, with median treatment durations of 5 days (interquartile range [IQR] 4-6) and 12 days (IQR 6-18), respectively. No recurrences were observed in either group. Infection-related readmissions occurred only in the long-course group (7.9%, n = 3; P = 0.49). Thirty-day mortality rates were 30% (short-course) vs 21.1% (long-course; P = 0.41), and the 90-day mortality rates were 30% vs 29%, respectively. Median post-bacteremia hospital LOS was shorter in the short-course group (10.5 vs 13 days; P = 0.68). The AEs were similar between groups. Conclusion: In this small exploratory cohort, short-course therapy (≤6 days) for uncomplicated VRE bacteremia was not associated with higher recurrence, readmission, or mortality than longer courses. These hypothesis-generating results support further studies on abbreviated treatments in carefully selected patients.","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":" ","pages":"87551225251396748"},"PeriodicalIF":1.5,"publicationDate":"2025-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12716972/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145804809","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An Analysis of Initial Loop Diuretic Dosing Strategies and Its Association with Time to Decongestion. 利尿剂初始循环给药策略及其与去充血时间的关系分析。

IF 1.5

Journal of Pharmacy Technology Pub Date : 2025-12-16 DOI: 10.1177/87551225251394953

Gregory Taylor, Jessica Starr, Nathan Pinner

{"title":"An Analysis of Initial Loop Diuretic Dosing Strategies and Its Association with Time to Decongestion.","authors":"Gregory Taylor, Jessica Starr, Nathan Pinner","doi":"10.1177/87551225251394953","DOIUrl":"10.1177/87551225251394953","url":null,"abstract":"Background: There is currently a lack of evidence on the optimal loop diuretic dosing strategy in cases of acute decompensated heart failure (ADHF). Current consensus recommendations suggest starting with a dose of at least 2 times the patient's home loop diuretic dose. Objective: This study assessed whether higher initial loop diuretic doses are associated with faster time to decongestion in hospitalized ADHF patients. Methods: This was a retrospective, single-center cohort of patients ≥19 years of age with ADHF who received intravenous (IV) loop diuretics between September 2022 and August 2023. Patients were separated into groups based on receipt of greater than or equal to 2.5 times their home loop diuretic dose (high-dose) and <2.5 times their home loop diuretic dose (low-dose). Results: In total, 114 patients were included with 74 patients in the high-dose group and 40 patients in the low-dose group. For the primary outcome of time to decongestion, there was no difference between the high-dose and the low-dose -0.37 (95% confidence interval [CI] = -1.32 to 0.58), P = 0.44. There was a difference in the need for diuretic intensification beyond 24 hours in favor of the high-dose group (P = 0.0001). Conclusion: Higher initial doses of loop diuretics did not lead to a more rapid time to decongestion. The high-dose group did require less diuretic intensification beyond 24 hours, but this was not associated with a shorter hospital length of stay (LOS).","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":" ","pages":"87551225251394953"},"PeriodicalIF":1.5,"publicationDate":"2025-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12708297/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145781109","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Treatment of Histoplasmosis With Posaconazole in the Setting of a Severe Itraconazole Hypersensitivity Reaction: A Case Report. 泊沙康唑治疗严重伊曲康唑超敏反应的组织胞浆菌病1例。

IF 1.5

Journal of Pharmacy Technology Pub Date : 2025-12-16 DOI: 10.1177/87551225251403429

Kinsey M Johannemann, Megan Z Roberts, Samir Allos, Madeline Belk, Spencer H Durham, Jonathan D Edwards

{"title":"Treatment of Histoplasmosis With Posaconazole in the Setting of a Severe Itraconazole Hypersensitivity Reaction: A Case Report.","authors":"Kinsey M Johannemann, Megan Z Roberts, Samir Allos, Madeline Belk, Spencer H Durham, Jonathan D Edwards","doi":"10.1177/87551225251403429","DOIUrl":"10.1177/87551225251403429","url":null,"abstract":"Objective: Itraconazole is recommended as the first-line oral treatment for pulmonary histoplasmosis. There is a paucity of data describing hypersensitivity reactions to itraconazole and lack of clarity on triazole antifungal cross-reactivity. Case: Approximately 9 hours after an initial dose of itraconazole 200 mg for treatment of chronic cavitary pulmonary histoplasmosis, a 72-year immunocompetent patient developed anaphylactic symptoms that abated with intervention. To resume histoplasmosis treatment in the setting of limited treatment options following nephrotoxicity that occurred while receiving amphotericin B, a single posaconazole 100 mg tablet was given and well tolerated by the patient. Subsequently a treatment course of posaconazole 300 mg began with confirmation of therapeutic drug levels prior to hospital discharge. Imaging after 2 months of posaconazole showed improvement in cavitation size. Conclusion: Posaconazole was a safe and effective alternative to itraconazole for chronic cavitary pulmonary histoplasmosis in this case. Further evaluation of mechanisms and management of triazole hypersensitivity reactions are warranted.","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":" ","pages":"87551225251403429"},"PeriodicalIF":1.5,"publicationDate":"2025-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12708300/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145781119","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pharmacological Management of Agitation in Hospitalized Elderly Patients: Evaluating Appropriateness and Standard Practices. 住院老年患者躁动的药理学管理：评估适当性和标准做法。

IF 1.5

Journal of Pharmacy Technology Pub Date : 2025-12-01 DOI: 10.1177/87551225251394195

Lindsay Brooks, Samantha Sotelo, Alberto Augsten

{"title":"Pharmacological Management of Agitation in Hospitalized Elderly Patients: Evaluating Appropriateness and Standard Practices.","authors":"Lindsay Brooks, Samantha Sotelo, Alberto Augsten","doi":"10.1177/87551225251394195","DOIUrl":"10.1177/87551225251394195","url":null,"abstract":"Background: Agitation in hospitalized older adults is common and can increase the risk of harm, mechanical ventilation duration, and prolonged hospital stays. Diagnosing and managing agitation in geriatric patients is especially complex due to overlapping symptoms with other conditions, altered pharmacokinetics, and increased sensitivity to adverse effects. This study aimed to evaluate the appropriateness of pharmacologic interventions for acute agitation in elderly inpatients and identify areas for improvement. Methods: A retrospective chart review was conducted at a public hospital in South Florida for patients ≥65 years old admitted between January 1 and June 30, 2024, who received medications for agitation management. Appropriateness was determined using Sedation-Agitation Scale (SAS) scores, medication administration patterns, and restraint use. Effectiveness, documentation quality, and adverse events were also assessed. Results: Among 72 encounters from 54 patients, 50% were classified as appropriate based on alignment with SAS scores and clinical restraint use. Effectiveness, defined as ≤1 as-needed dose per day, was observed in 68.1% of cases. Restraint use was significantly associated with appropriateness (χ² = 23.63, P < 0.0001), and although paradoxical, inappropriate regimens were more often effective (χ² = 5.39, P = 0.0203). Adverse effects were documented in only 6.9% of cases, and complete documentation was present in 27.8% of encounters. Conclusion: Findings reveal inconsistencies in agitation management and documentation, with frequent overtreatment and underreporting. There is a clear need for standardized, geriatric-focused treatment protocols and improved documentation practices to optimize safety and effectiveness.","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":" ","pages":"87551225251394195"},"PeriodicalIF":1.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12668992/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145668488","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clesrovimab for the Prevention of Respiratory Syncytial Virus Lower Respiratory Tract Disease in Infants. 克列罗维单抗预防婴儿呼吸道合胞病毒下呼吸道疾病。

IF 1.5

Journal of Pharmacy Technology Pub Date : 2025-11-29 DOI: 10.1177/87551225251392119

Bradley Phillips, Christopher Jackson, Jordan Phillips

{"title":"Clesrovimab for the Prevention of Respiratory Syncytial Virus Lower Respiratory Tract Disease in Infants.","authors":"Bradley Phillips, Christopher Jackson, Jordan Phillips","doi":"10.1177/87551225251392119","DOIUrl":"10.1177/87551225251392119","url":null,"abstract":"Objective: To assess the clinical utility of clesrovimab-cfor (Enflonsia®), a newly Food and Drug Administration (FDA)-approved monoclonal antibody, for the prevention of respiratory syncytial virus (RSV) lower respiratory tract infections in infants. Data Sources: A literature search was conducted using the key words clesrovimab, RSV, pediatric, infant, and nirsevimab. Data were also extracted from Centers for Disease Control and Prevention (CDC), Advisory Committee on Immunization Practices (ACIP), FDA prescribing information, and manufacturer data were reviewed. Study Selection and Data Extraction: English-language studies assessing the pharmacokinetics, pharmacodynamics, efficacy, and safety of clesrovimab were included. Key clinical trials (CLEVER and SMART) and cost-effectiveness models were reviewed. Data Synthesis: Clesrovimab binds to a conserved site on the RSV F protein, targeting both pre- and postfusion forms. In the CLEVER trial, it reduced RSV-associated medical visits by 60.4% and hospitalizations by 84.2%. The SMART trial showed comparable efficacy and safety to palivizumab. Adverse events were mild and injection-site related. No cross-resistance was observed with variants resistant to other monoclonal antibodies. Pharmacokinetics support single-dose administration with a half-life of 44 days. Conclusion: Clesrovimab offers simplified dosing, favorable safety, and potential cost savings compared with palivizumab and nirsevimab. While nirsevimab has a longer half-life, clesrovimab's unique binding site and room-temperature stability offer practical advantages. Lack of head-to-head comparisons and limited second-season data warrant further study. Clesrovimab is a promising addition to RSV prevention strategies, offering effective, safe, and accessible immunization for infants. Ongoing research will clarify its role in high-risk populations and broader clinical use.","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":" ","pages":"87551225251392119"},"PeriodicalIF":1.5,"publicationDate":"2025-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12664777/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145654570","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0